# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
160, Journal, 0, 14, "Arch Med Res .", "", "<http://ctro/data#Publication_37790> <http://ctro/data#hasJournal> \"Arch Med Res .\"."
0, PublicationYear, 15, 19, "2006", "", "<http://ctro/data#Publication_37790> <http://ctro/data#hasPublicationYear> \"2006\"."
161, Title, 49, 150, "Therapy in type 2 diabetes : insulin glargine vs . NPH insulin both in combination with glimepiride .", "", "<http://ctro/data#Publication_37790> <http://ctro/data#hasTitle> \"Therapy in type 2 diabetes : insulin glargine vs . NPH insulin both in combination with glimepiride .\"."
1, Type2Diabetes, 60, 75, "type 2 diabetes", "", 
2, InsulinGlargine, 78, 94, "insulin glargine", "", 
3, IsophaneInsulin_NPH, 100, 111, "NPH insulin", "", 
4, Glimepiride, 137, 148, "glimepiride", "", 
5, Author, 151, 166, "Eliaschewitz FG", "", "<http://ctro/data#Publication_37790> <http://ctro/data#hasAuthor> \"Eliaschewitz FG\"."
6, Author, 175, 182, "Calvo C", "", "<http://ctro/data#Publication_37790> <http://ctro/data#hasAuthor> \"Calvo C\"."
7, Author, 185, 195, "Valbuena H", "", "<http://ctro/data#Publication_37790> <http://ctro/data#hasAuthor> \"Valbuena H\"."
8, Author, 198, 204, "Ruiz M", "", "<http://ctro/data#Publication_37790> <http://ctro/data#hasAuthor> \"Ruiz M\"."
9, Author, 207, 216, "Aschner P", "", "<http://ctro/data#Publication_37790> <http://ctro/data#hasAuthor> \"Aschner P\"."
10, Author, 219, 228, "Villena J", "", "<http://ctro/data#Publication_37790> <http://ctro/data#hasAuthor> \"Villena J\"."
11, Author, 231, 241, "Ramirez LA", "", "<http://ctro/data#Publication_37790> <http://ctro/data#hasAuthor> \"Ramirez LA\"."
12, Author, 244, 253, "Jimenez J", "", "<http://ctro/data#Publication_37790> <http://ctro/data#hasAuthor> \"Jimenez J\"."
13, Brazil, 353, 359, "Brazil", "", "<http://ctro/data#Population_37823> <http://ctro/data#hasCountry> <http://ctro/data#Brazil>."
14, Type2Diabetes, 403, 418, "Type 2 diabetes", "", 
15, Type2Diabetes, 421, 425, "T2DM", "", 
16, OralAntidiabeticAgent, 490, 513, "oral antidiabetic drugs", "", 
17, OralAntidiabeticAgent, 516, 520, "OADs", "", 
18, Insulin, 525, 532, "Insulin", "", 
19, Hypoglycemia, 621, 633, "hypoglycemia", "", 
162, ObjectiveDescription, 636, 846, "This study compared the efficacy and safety of insulin glargine and NPH insulin , both in combination with a once - daily fixed dose of glimepiride , in terms of glycemic control and incidence of hypoglycemia .", "", "<http://ctro/data#ClinicalTrial_37804> <http://ctro/data#hasObjectiveDescription> \"This study compared the efficacy and safety of insulin glargine and NPH insulin , both in combination with a once - daily fixed dose of glimepiride , in terms of glycemic control and incidence of hypoglycemia .\"."
20, InsulinGlargine, 683, 699, "insulin glargine", "", 
21, IsophaneInsulin_NPH, 704, 715, "NPH insulin", "", 
104, Frequency, 745, 757, "once - daily", "", "<http://ctro/data#Intervention_37879> <http://ctro/data#hasFrequency> \"once - daily\". <http://ctro/data#Intervention_37885> <http://ctro/data#hasFrequency> \"once - daily\"."
23, Glimepiride, 772, 783, "glimepiride", "", 
24, Hypoglycemia, 832, 844, "hypoglycemia", "", 
25, OpenLabel, 865, 877, "open - label", "", "<http://ctro/data#ClinicalTrial_37804> <http://ctro/data#hasCTDesign> <http://ctro/data#OpenLabel>."
27, Duration, 880, 889, "24 - week", "", "<http://ctro/data#ClinicalTrial_37804> <http://ctro/data#hasCTduration> \"24 - week\"."
26, Randomized, 890, 900, "randomized", "", "<http://ctro/data#ClinicalTrial_37804> <http://ctro/data#hasCTDesign> <http://ctro/data#Randomized>."
28, Multicenter, 910, 938, "ten Latin American countries", "", "<http://ctro/data#ClinicalTrial_37804> <http://ctro/data#hasCTDesign> <http://ctro/data#Multicenter>."
29, Type2Diabetes, 941, 945, "T2DM", "", 
33, Precondition, 941, 1023, "T2DM patients poorly controlled on OADs ( HbA1c > or = 7 . 5 and < or = 10 . 5 % )", "", "<http://ctro/data#Population_37823> <http://ctro/data#hasPrecondition> \"T2DM patients poorly controlled on OADs ( HbA1c > or = 7 . 5 and < or = 10 . 5 % )\"."
30, OralAntidiabeticAgent, 976, 980, "OADs", "", 
31, HbA1c, 983, 988, "HbA1c", "", 
32, Percentage, 1020, 1021, "%", "", 
34, Glimepiride, 1033, 1044, "glimepiride", "", "<http://ctro/data#Medication_37891> <http://ctro/data#hasDrug> <http://ctro/data#Glimepiride>."
35, InsulinGlargine, 1050, 1066, "insulin glargine", "", "<http://ctro/data#Medication_37898> <http://ctro/data#hasDrug> <http://ctro/data#InsulinGlargine>."
36, NumberPatientsArm, 1073, 1076, "231", "", "<http://ctro/data#Arm_37861> <http://ctro/data#hasNumberPatientsArm> \"231\"."
37, IsophaneInsulin_NPH, 1082, 1093, "NPH insulin", "", "<http://ctro/data#Medication_37905> <http://ctro/data#hasDrug> <http://ctro/data#IsophaneInsulin_NPH>."
38, NumberPatientsArm, 1100, 1103, "250", "", "<http://ctro/data#Arm_37870> <http://ctro/data#hasNumberPatientsArm> \"250\"."
51230, DoseDescription, 1106, 1140, "using a forced titration algorithm", "", "<http://ctro/data#Medication_37891> <http://ctro/data#hasDoseDescription> \"using a forced titration algorithm\". <http://ctro/data#Medication_37898> <http://ctro/data#hasDoseDescription> \"using a forced titration algorithm\". <http://ctro/data#Medication_37905> <http://ctro/data#hasDoseDescription> \"using a forced titration algorithm\"."
39, Duration, 1187, 1196, "24 - week", "", 
158, Mean, 1197, 1201, "mean", "", 
40, HbA1c, 1213, 1218, "HbA1c", "", 
41, InsulinGlargine, 1231, 1247, "Insulin glargine", "", 
42, IsophaneInsulin_NPH, 1252, 1263, "NPH insulin", "", 
43, HbA1c, 1281, 1286, "HbA1c", "", "<http://ctro/data#Endpoint_37831> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c>."
159, Mean, 1309, 1313, "mean", "", "<http://ctro/data#Mean_37833> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Mean>. <http://ctro/data#Endpoint_37831> <http://ctro/data#hasAggregationMethod> <http://ctro/data#Mean_37833>."
124, DiffGroupAbsValue, 1325, 1334, "- 0 . 047", "", "<http://ctro/data#DiffBetweenGroups_37966> <http://ctro/data#hasDiffGroupAbsValue> \"- 0 . 047\"."
125, ConfIntervalDiff, 1337, 1364, "90 % CI - 0 . 232 , 0 . 138", "", "<http://ctro/data#DiffBetweenGroups_37966> <http://ctro/data#hasConfIntervalDiff> \"90 % CI - 0 . 232 , 0 . 138\"."
45874, SubGroupDescription, 1367, 1390, "per - protocol analysis", "", "<http://ctro/data#Outcome_37912> <http://ctro/data#hasSubGroupDescription> \"per - protocol analysis\". <http://ctro/data#Outcome_37939> <http://ctro/data#hasSubGroupDescription> \"per - protocol analysis\"."
80, PerProtocol, 1367, 1381, "per - protocol", "", "<http://ctro/data#ClinicalTrial_37804> <http://ctro/data#hasAnalysisApproach> <http://ctro/data#PerProtocol>."
46, NocturnalHypoglycemia, 1405, 1427, "nocturnal hypoglycemia", "", "<http://ctro/data#Endpoint_37836> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#NocturnalHypoglycemia>."
47, InsulinGlargine, 1457, 1473, "insulin glargine", "", 
48, IsophaneInsulin_NPH, 1479, 1490, "NPH insulin", "", 
49, PercentageAffected, 1493, 1499, "16 . 9", "", "<http://ctro/data#Outcome_37975> <http://ctro/data#hasPercentageAffected> \"16 . 9\"."
50, PercentageAffected, 1505, 1511, "30 . 0", "", "<http://ctro/data#Outcome_38002> <http://ctro/data#hasPercentageAffected> \"30 . 0\"."
51, PvalueDiff, 1516, 1526, "p < 0 . 01", "", "<http://ctro/data#DiffBetweenGroups_38029> <http://ctro/data#hasPvalueDiff> \"p < 0 . 01\"."
52, InsulinGlargine, 1568, 1584, "insulin glargine", "", 
53, HbA1c_target, 1627, 1649, "HbA1c levels < 7 . 0 %", "", "<http://ctro/data#Endpoint_37841> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c_target>."
54, Percentage, 1648, 1649, "%", "", 
55, Hypoglycemia, 1658, 1670, "hypoglycemia", "", "<http://ctro/data#Endpoint_37846> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#Hypoglycemia>."
57, PercentageAffected, 1673, 1675, "27", "", "<http://ctro/data#Outcome_38038> <http://ctro/data#hasPercentageAffected> \"27\"."
58, PercentageAffected, 1681, 1683, "17", "", "<http://ctro/data#Outcome_38065> <http://ctro/data#hasPercentageAffected> \"17\"."
59, PvalueDiff, 1688, 1699, "p = 0 . 014", "", "<http://ctro/data#DiffBetweenGroups_38092> <http://ctro/data#hasPvalueDiff> \"p = 0 . 014\"."
45873, SubGroupDescription, 1702, 1725, "per - protocol analysis", "", "<http://ctro/data#Outcome_38038> <http://ctro/data#hasSubGroupDescription> \"per - protocol analysis\". <http://ctro/data#Outcome_38065> <http://ctro/data#hasSubGroupDescription> \"per - protocol analysis\"."
78, PerProtocol, 1702, 1716, "per - protocol", "", 
62, EndPointDescription, 1758, 1780, "treatment satisfaction", "", "<http://ctro/data#EndPointDescription_37852> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_37851> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_37852>."
60, InsulinGlargine, 1798, 1814, "insulin glargine", "", 
61, IsophaneInsulin_NPH, 1820, 1831, "NPH insulin", "", 
63, PvalueDiff, 1834, 1844, "p < 0 . 02", "", "<http://ctro/data#DiffBetweenGroups_38155> <http://ctro/data#hasPvalueDiff> \"p < 0 . 02\"."
45875, SubGroupDescription, 1847, 1860, "full analysis", "", "<http://ctro/data#Outcome_38101> <http://ctro/data#hasSubGroupDescription> \"full analysis\". <http://ctro/data#Outcome_38128> <http://ctro/data#hasSubGroupDescription> \"full analysis\"."
68, EndPointDescription, 1883, 1952, "patients who lost time from work or normal activities due to diabetes", "", "<http://ctro/data#EndPointDescription_37857> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_37856> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_37857>."
64, InsulinGlargine, 1968, 1984, "insulin glargine", "", 
65, IsophaneInsulin_NPH, 1990, 1993, "NPH", "", 
66, PercentageAffected, 1996, 2001, "1 . 8", "", "<http://ctro/data#Outcome_38164> <http://ctro/data#hasPercentageAffected> \"1 . 8\"."
67, PercentageAffected, 2007, 2012, "3 . 3", "", "<http://ctro/data#Outcome_38191> <http://ctro/data#hasPercentageAffected> \"3 . 3\"."
45872, SubGroupDescription, 2017, 2030, "full analysis", "", "<http://ctro/data#Outcome_38164> <http://ctro/data#hasSubGroupDescription> \"full analysis\". <http://ctro/data#Outcome_38191> <http://ctro/data#hasSubGroupDescription> \"full analysis\"."
163, ConclusionComment, 2049, 2276, "In patients with T2DM , inadequately controlled on OADs , once - daily insulin glargine plus glimepiride is effective in improving metabolic control with a reduced incidence of nocturnal hypoglycemia compared with NPH insulin .", "", "<http://ctro/data#ClinicalTrial_37804> <http://ctro/data#hasConclusionComment> \"In patients with T2DM , inadequately controlled on OADs , once - daily insulin glargine plus glimepiride is effective in improving metabolic control with a reduced incidence of nocturnal hypoglycemia compared with NPH insulin .\"."
69, Type2Diabetes, 2066, 2070, "T2DM", "", 
70, OralAntidiabeticAgent, 2100, 2104, "OADs", "", 
72, Frequency, 2107, 2119, "once - daily", "", 
73, InsulinGlargine, 2120, 2136, "insulin glargine", "", 
74, Glimepiride, 2142, 2153, "glimepiride", "", 
75, NocturnalHypoglycemia, 2226, 2248, "nocturnal hypoglycemia", "", 
76, IsophaneInsulin_NPH, 2263, 2274, "NPH insulin", "", 
77, PMID, 2284, 2292, "16715577", "", "<http://ctro/data#Publication_37790> <http://ctro/data#hasPMID> \"16715577\"."
